Equator

Methods	Type of RCT: 1:3 parallel‐group, double‐blind dose‐ranging RCT Settings: outpatient care Duration: 24 weeks Start and stop dates: NA
Participants	Number of participants: 248 (247 with baseline data) Number lost to follow‐up: 20 Women: 107 (43%) Age (SD), years: 64 (8) History of CVD: 129 (52%) Participants with FH: NA Participants with established CHD or CHD equivalent risk (not defined further)
Interventions	Background therapy: standard of care, potentially including statin therapy Randomised therapy: 24 weeks of RG7652 (MPSK3169A) every 4, 8, or 12 weeks vs placebo RUG7652 dose: 5 dosage regimens were administered: 200 mg every 8 weeks, 400 mg every 8 weeks, 800 mg every 12 weeks, 400 mg every 4 weeks, 800 mg every 8 weeks, resulting in a 2‐week equivalent dose of 50 mg to 200 mg
Outcomes	Lipids, any adverse events, CVD, all‐cause mortality
Notes	Reduction in lipids was given as an overall P value and as a range of effects. Effect was averaged and standard error was calculated assuming a standard normal distribution. This results in a very conservative estimate of precision
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Only an abstract/poster was available
Allocation concealment (selection bias)	Unclear risk	Only an abstract/poster was available
Blinding of participants and personnel (performance bias) LDL‐C	Unclear risk	Only an abstract/poster was available
Blinding of outcome assessment (detection bias) LDL‐C	Unclear risk	Only an abstract/poster was available. Unknown if a central laboratory was used
Incomplete outcome data (attrition bias) All outcomes	High risk	1 participant was excluded from modified ITT population, and 19 participants (7.66%) did not complete the study
Selective reporting (reporting bias)	Unclear risk	Full paper has not yet been published
Other bias	High risk	Funded by F. Hoffman‐La Roche Ltd